Skip to main content
. 2021 Mar 4;9(5):438–440. doi: 10.1016/S2213-2600(21)00127-2

Figure.

Figure

Mortality risk in patients admitted to hospital with COVID-19 and treated with IL-6 inhibitors (tocilizumab or sarilumab) or a control

Heterogeneity between groups p=0·976. Studies are weighted in terms of their contribution to the overall estimate. Weights are taken from the random effects model using REML. The vertical dotted line shows the point estimate of the combined effect for reference to the null line (solid) and the point estimates of the individual studies. REML=restricted maximum likelihood.